And in the same matter, at the 2012 Biomed conference, Bio-Jerusalem announced a basket of support grants for Biomed companies in Jerusalem as part of the Marom plan for the economic development of the city
This coming Thursday, 24/5/2012, a conference and the first of its kind will be held in the Jerusalem Municipality building in the capacity of Mayor Nir Barkat and Jeffrey Miller, the representative of the billionaire Steve Burrill, which will be held by the "Jerusalem Business Relations Forum".
As part of the conference, the "Boril Israel" biomed investment fund will be launched, the purpose of which is to examine and locate Israeli biomed companies, especially Jerusalem companies, that are at the beginning of their journey and to invest in them. Mr. Jeffrey Miller, who sits on the board of the fund, will present the significant investment policy that the fund intends to invest in the biomed projects.
"This is the first initiative of the 'Jerusalem Business Relations Forum' on the topic of biomed, an opening mine for the future," says forum organizer Joe Van Zwaren. "Jerusalem leads biomed research in Israel, with its branched academic research institutions, and concentrates half of the research activity in the field of biomed. For this reason, Nir Barkat together with the Jerusalem Municipality decided to give the field of biomed a top priority."
Professor Leo Yoskovich, from the Hebrew University of Jerusalem, believes that the "Jerusalem Business Relations Forum" on the issue of biomed, has the potential to promote academic research, laboratory research and the biomed industry in Jerusalem by creating a synergy that will help Nir Barkat to advance this field to the top of priorities "
The committee of the "Jerusalem Business Relations Forum" on the issue of biomed consists of Esther Muscatel Mendelson from "Kern-Tech", Daniel Green from the law firm of Yigal Arnon & Co. and Josh Hekster from Bioline R.X. and Ms. Abigail Frige.
Interim grants up to NIS 3.9 million to Biomed companies that will establish or expand their operations in Jerusalem
Separately today, BioJerusalem, at the Biomed Israel 2012 conference, an initiative of the Jerusalem Development Authority that aims to promote the life sciences industry in the capital, presented a basket of far-reaching benefits to Biomed companies that establish, expand or move their operations to Jerusalem. The grants are given as part of the Marom Program, a multi-year plan to strengthen the economy of Jerusalem approved by the Israeli government in 2011, which allocates NIS 71.4 million to research and development and industry in the field of biotechnology in the capital between 2011-2016 for the purpose of strengthening Jerusalem as a biotechnology center.
With the intention of supporting the biomed industry in the capital and encouraging the creation of new jobs, the Prime Minister's Office, the Jerusalem Municipality and the Jerusalem Development Authority are offering a precedent grant of up to NIS 3.9 million to established companies in the field of life sciences that choose to establish or expand their plants in Jerusalem. A unique grant of up to NIS 576,000 was also given to the company, intended for start-up companies in the biomed field. In addition to supporting biomed companies, the Marom program also supports research and development infrastructure, which includes grants to industry service providers as well as the establishment of subsidized laboratory complexes for rent to small and medium-sized companies. In addition to these benefits, Jerusalem is the only city in the center of the country that enjoys the status of a National Priority Area A, which grants technology companies the best grants and tax breaks in the country. Companies operating in Jerusalem can also benefit from a series of additional municipal benefits granted by the Jerusalem Development Authority.
Moti Hazan, CEO of the Jerusalem Development Authority said, "Jerusalem is the only city in Israel for which there is a government policy aimed at encouraging the biomed sector. There is cooperation here at the highest levels between the Prime Minister's Office, the Ministry of Finance, the Jerusalem Development Authority and the Jerusalem Municipality to leverage the relative advantages that already exist in the city, for the purpose of building a leading biomed industry in Jerusalem, and turning the city into the biomed capital of Israel."
Chen Levin, director of Bio-Jerusalem, said, "As part of the Marom program, we have significantly increased the unique benefits for biomed companies, and we encourage established and young companies as well as entrepreneurs in the field of life sciences to contact us to enjoy these support and benefits. In Jerusalem, there is a thriving biomed cluster, and notable advantages in the biomed field. The city is a powerhouse of knowledge and innovation in the life sciences and medicine that originates from its leading research institutions and an impressive biomed industry, which are based on professional human capital and unique research and development infrastructures. The Marom program allows us to increase our support for the biomed cluster in the capital to make Jerusalem the heart of the Israeli biomed industry."
Bio-Jerusalem announces a basket of support grants for biomed companies in Jerusalem as part of the Marom program for the economic development of the city.
